Patents by Inventor Joycelyn Entwistle
Joycelyn Entwistle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9822182Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.Type: GrantFiled: October 2, 2014Date of Patent: November 21, 2017Assignee: VIVENTIA BIO INC.Inventors: Jeannick Cizeau, Arjune Premsukh, Shilpa Chooniedass, Glen MacDonald, Joycelyn Entwistle
-
Publication number: 20160237164Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.Type: ApplicationFiled: October 2, 2014Publication date: August 18, 2016Inventors: Jeannick CIZEAU, Arjune PREMSUKH, Shilpa CHOONIEDASS, Glen MACDONALD, Joycelyn ENTWISTLE
-
Publication number: 20150197575Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: ApplicationFiled: January 23, 2015Publication date: July 16, 2015Inventors: Nicholas Ronald GLOVER, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Georges Bosc, Francina C. Chahal
-
Patent number: 8969540Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: GrantFiled: January 17, 2013Date of Patent: March 3, 2015Assignee: Viventia Bio Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, Francina C. Chahal
-
Publication number: 20150018526Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: ApplicationFiled: April 1, 2014Publication date: January 15, 2015Applicant: Merck Patent GmbHInventors: Matthew BAKER, Francis J. CARR, Koen HELLENDOORN, Jeannick CIZEAU, Glen C. MACDONALD, Joycelyn ENTWISTLE, Denis G. BOSC, Nicholas R. GLOVER
-
Patent number: 8716234Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: GrantFiled: May 21, 2010Date of Patent: May 6, 2014Assignee: Merck Patent GmbHInventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Patent number: 8697075Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: GrantFiled: November 16, 2011Date of Patent: April 15, 2014Assignee: Viventia Bio Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
-
Publication number: 20130217865Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: ApplicationFiled: January 17, 2013Publication date: August 22, 2013Applicant: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, Francina C. Chahal
-
Patent number: 8383117Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: GrantFiled: June 10, 2005Date of Patent: February 26, 2013Assignee: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Georges Bosc, Francina C. Chahal
-
Patent number: 8372954Abstract: Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and/or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.Type: GrantFiled: December 21, 2001Date of Patent: February 12, 2013Assignee: National Research Council of CanadaInventors: Jamshid Tanha, Joycelyn Entwistle, Saran Narang, Michael Dan, Colin R. Mackenzie, Carole Grad
-
Publication number: 20120128723Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: ApplicationFiled: November 16, 2011Publication date: May 24, 2012Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: Francina C. CHAHAL, Joycelyn ENTWISTLE, Jeannick CIZEAU, Nicholas Ronald GLOVER, Glen Christopher MACDONALD
-
Patent number: 8084576Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: GrantFiled: December 21, 2005Date of Patent: December 27, 2011Assignee: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
-
Publication number: 20100254982Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: ApplicationFiled: December 21, 2005Publication date: October 7, 2010Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
-
Publication number: 20100254964Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: ApplicationFiled: May 21, 2010Publication date: October 7, 2010Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Patent number: 7750136Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: GrantFiled: January 9, 2008Date of Patent: July 6, 2010Assignee: Merck Patent GmbHInventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Publication number: 20080219994Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: ApplicationFiled: January 9, 2008Publication date: September 11, 2008Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Patent number: 7339031Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: GrantFiled: March 18, 2005Date of Patent: March 4, 2008Assignee: Merck Patent GmbHInventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Publication number: 20070292441Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: ApplicationFiled: June 10, 2005Publication date: December 20, 2007Inventors: Nicholas Glover, Glen MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, Francina Chahal
-
Publication number: 20050238642Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: ApplicationFiled: March 18, 2005Publication date: October 27, 2005Inventors: Matthew Baker, Francis Carr, Koen Hellendoorn, Jeannick Cizeau, Glen MacDonald, Joycelyn Entwistle, Denis Bosc, Nicholas Glover
-
Publication number: 20050164180Abstract: Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and/or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.Type: ApplicationFiled: December 21, 2001Publication date: July 28, 2005Inventors: Jamshid Tanha, Joycelyn Entwistle, Saran Narang, Michael Dan, Colin Mackenzie, Howard Kaplan, Carole Grad